Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,604.00 GBX | -0.34% | -4.01% | +10.61% |
09-18 | European Equities Close Lower in Wednesday Trading; EU, Euro Area Inflation Declines in August | MT |
09-18 | GSK Settles Two California Lawsuits Related to Zantac | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 33.75B | 34.1B | 34.11B | 29.32B | 30.33B | |||||
Total Revenues | 33.75B | 34.1B | 34.11B | 29.32B | 30.33B | |||||
Cost of Goods Sold, Total | 10.79B | 10.89B | 11.45B | 9.41B | 8.39B | |||||
Gross Profit | 22.96B | 23.21B | 22.66B | 19.92B | 21.94B | |||||
Selling General & Admin Expenses, Total | 10.6B | 10.5B | 10.19B | 8.18B | 9.16B | |||||
R&D Expenses | 4.4B | 4.68B | 4.88B | 5.15B | 5.82B | |||||
Other Operating Expenses | -606M | -455M | -373M | -737M | -1.44B | |||||
Other Operating Expenses, Total | 14.4B | 14.73B | 14.69B | 12.6B | 13.54B | |||||
Operating Income | 8.56B | 8.48B | 7.97B | 7.32B | 8.4B | |||||
Interest Expense, Total | -877M | -860M | -775M | -819M | -710M | |||||
Interest And Investment Income | 79M | 39M | 26M | 62M | 108M | |||||
Net Interest Expenses | -798M | -821M | -749M | -757M | -602M | |||||
Income (Loss) On Equity Invest. | 74M | 33M | 33M | -2M | -5M | |||||
Currency Exchange Gains (Loss) | - | - | - | - | - | |||||
Other Non Operating Income (Expenses) | -12M | -21M | -4M | -46M | -75M | |||||
EBT, Excl. Unusual Items | 7.83B | 7.67B | 7.25B | 6.52B | 7.72B | |||||
Restructuring Charges | -1.11B | -1.53B | -628M | -321M | -382M | |||||
Gain (Loss) On Sale Of Investments | 129M | -242M | 1M | 256M | -121M | |||||
Gain (Loss) On Sale Of Assets | 399M | 3.01B | 591M | 215M | 61M | |||||
Asset Writedown | -83M | -263M | -322M | -296M | -398M | |||||
Legal Settlements | -363M | -231M | -52M | 922M | - | |||||
Other Unusual Items | -579M | -1.45B | -1.39B | -1.66B | -817M | |||||
EBT, Incl. Unusual Items | 6.22B | 6.97B | 5.44B | 5.63B | 6.06B | |||||
Income Tax Expense | 953M | 580M | 346M | 707M | 756M | |||||
Earnings From Continuing Operations | 5.27B | 6.39B | 5.1B | 4.92B | 5.31B | |||||
Earnings Of Discontinued Operations | - | - | - | 10.5B | - | |||||
Net Income to Company | 5.27B | 6.39B | 5.1B | 15.42B | 5.31B | |||||
Minority Interest | -623M | -639M | -711M | -460M | -380M | |||||
Net Income - (IS) | 4.64B | 5.75B | 4.38B | 14.96B | 4.93B | |||||
Net Income to Common Incl Extra Items | 4.64B | 5.75B | 4.38B | 14.96B | 4.93B | |||||
Net Income to Common Excl. Extra Items | 4.64B | 5.75B | 4.38B | 4.46B | 4.93B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 1.17 | 1.44 | 1.1 | 3.71 | 1.22 | |||||
Basic EPS - Continuing Operations | 1.17 | 1.44 | 1.1 | 1.11 | 1.22 | |||||
Basic Weighted Average Shares Outstanding | 3.96B | 3.98B | 4B | 4.03B | 4.05B | |||||
Net EPS - Diluted | 1.16 | 1.43 | 1.08 | 3.66 | 1.2 | |||||
Diluted EPS - Continuing Operations | 1.16 | 1.43 | 1.08 | 1.09 | 1.2 | |||||
Diluted Weighted Average Shares Outstanding | 4.01B | 4.03B | 4.05B | 4.08B | 4.11B | |||||
Normalized Basic EPS | 1.08 | 1.04 | 0.95 | 0.9 | 1.1 | |||||
Normalized Diluted EPS | 1.06 | 1.03 | 0.94 | 0.88 | 1.08 | |||||
Dividend Per Share | 1 | 1 | 1 | 0.61 | 0.58 | |||||
Payout Ratio | 85.1 | 69.18 | 91.2 | 23.18 | 45.6 | |||||
American Depositary Receipts Ratio (ADR) | 2 | 2 | 2 | 2 | 2 | |||||
Supplemental Items | ||||||||||
EBITDA | 10.45B | 10.37B | 9.9B | 9.47B | 10.3B | |||||
EBITA | 9.43B | 9.38B | 8.92B | 8.41B | 9.41B | |||||
EBIT | 8.56B | 8.48B | 7.97B | 7.32B | 8.4B | |||||
EBITDAR | 10.48B | 10.4B | 9.92B | 9.49B | 10.33B | |||||
Effective Tax Rate - (Ratio) | 15.32 | 8.32 | 6.36 | 12.56 | 12.47 | |||||
Current Domestic Taxes | - | - | - | - | - | |||||
Current Foreign Taxes | - | - | - | - | - | |||||
Total Current Taxes | 1.14B | 1.27B | 1.35B | 1.49B | 1.62B | |||||
Total Deferred Taxes | -183M | -693M | -1B | -784M | -865M | |||||
Normalized Net Income | 4.27B | 4.16B | 3.82B | 3.61B | 4.45B | |||||
Interest Capitalized | - | 15M | 16M | 21M | 36M | |||||
Interest on Long-Term Debt | 65M | 55M | 47M | 51M | 74M | |||||
Non-Cash Pension Expense | 75M | 82M | 50M | 37M | 73M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 1.57B | 1.78B | 1.81B | 735M | 835M | |||||
Selling and Marketing Expenses | 1.57B | 1.78B | - | - | - | |||||
Research And Development Expense From Footnotes | 4.57B | 5.1B | 5.28B | 5.49B | 6.22B | |||||
Net Rental Expense, Total | 29M | 27M | 20M | 17M | 27M | |||||
Imputed Operating Lease Interest Expense | 7.19M | 6.56M | 4.93M | 5.06M | 8.26M | |||||
Imputed Operating Lease Depreciation | 21.81M | 20.44M | 15.07M | 11.94M | 18.74M | |||||
Stock-Based Comp., Other (Total) | 432M | 393M | 404M | 346M | 307M | |||||
Total Stock-Based Compensation | 432M | 393M | 404M | 346M | 307M |